ArticleRheumatology and therapy2020

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany.

Klaus Krüger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.